Results 121 to 130 of about 24,922 (273)

Application of PCR to a clinical and environmental investigation of a case of equine botulism [PDF]

open access: yes, 1994
PCR for the detection of botulinum neurotoxin gene types A to E was used in the investigation of a case of equine botulism. Samples from a foal diagnosed with toxicoinfectious botulism in 1985 were reanalyzed by PCR and the mouse bioassay in conjunction ...
Desmarchelier P.M.   +5 more
core   +1 more source

Levodopa‐Carbidopa Intestinal Gel Improves Dyskinesia in Parkinson's Disease: Post Hoc Analysis from the COSMOS Study

open access: yesMovement Disorders Clinical Practice, Volume 13, Issue 1, Page 98-107, January 2026.
Abstract Background Dyskinesia is a debilitating complication of dopaminergic therapy in advanced Parkinson's disease. Objectives To evaluate the effect of levodopa‐carbidopa intestinal gel (LCIG) on dyskinesia burden. Methods This is a post hoc analysis of the retrospective, observational COmedication Study assessing Mono‐ and cOmbination therapy with
Alfonso Fasano   +11 more
wiley   +1 more source

Submandibular gland botulinum neurotoxin A injection for predicting the outcome of submandibular duct relocation in drooling: a retrospective cohort study [PDF]

open access: bronze, 2019
Saskia E. Kok   +5 more
openalex   +1 more source

Botulinum toxin therapy: functional silencing of salivary disorders. [PDF]

open access: yes, 2017
Botulinum toxin (BTX) is a neurotoxic protein produced by Clostridium botulinum, an anaerobic bacterium. BTX therapy is a safe and effective treatment when used for functional silencing of the salivary glands in disorders such as sialoceles and salivary ...
Lovato, A   +4 more
core  

Subcutaneous Apomorphine Infusion Initiation Is Associated with Impulse Control Disorder Attenuation in Advanced Parkinson's Disease Patients: Insights from the French NS‐Park Cohort

open access: yesMovement Disorders Clinical Practice, Volume 13, Issue 1, Page 142-153, January 2026.
Abstract Background Impulse control disorders (ICD) are common non‐motor complications in Parkinson's disease (PD), particularly in patients receiving oral dopamine agonists (DA). Continuous subcutaneous apomorphine infusion (CSAI) is a device‐aided therapy for advanced PD, but its effects on ICD remain underexplored in real‐world settings.
Clément Desjardins   +249 more
wiley   +1 more source

Basal Forebrain Volume Predicts Disease Conversion in Prodromal Synucleinopathy

open access: yesMovement Disorders Clinical Practice, Volume 13, Issue 1, Page 198-207, January 2026.
Abstract Background Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal stage of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The basal forebrain (BF), a key cholinergic structure, is a site of known pathology in later stages of Lewy body disorders.
Lachlan Churchill   +5 more
wiley   +1 more source

The Mild Behavioral Impairment Checklist for Parkinson's Disease: An Ancillary Instrument in Cognitive Assessment

open access: yesMovement Disorders Clinical Practice, Volume 13, Issue 1, Page 108-119, January 2026.
Abstract Background Mild behavioral impairment (MBI) is a syndrome characterized by the later‐life onset of neuropsychiatric symptoms (NPS) and serves as a potential marker for dementia. In Parkinson's disease (PD), MBI has been associated with worse cognition, cortical atrophy, and altered connectivity.
Gabriel D. Pinilla‐Monsalve   +4 more
wiley   +1 more source

Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, Volume 13, Issue 1, Page 181-190, January 2026.
Abstract Background As Parkinson's disease (PD) progresses, managing symptoms becomes increasingly difficult. Foslevodopa/foscarbidopa (LDp/CDp), a 24‐hour/day continuous subcutaneous infusion of levodopa/carbidopa (LD/CD) prodrugs, improves motor complications.
Jason Aldred   +11 more
wiley   +1 more source

Neurotropic Effect of Botulinum Toxin and the Potential of Specific Serum Therapy in Botulism (Review)

open access: yesБезопасность и риск фармакотерапии
INTRODUCTION. The outbreak of foodborne botulism that occurred in Russia in June 2024 once again demonstrated the danger of this rather rare but severe infectious disease caused by ingesting botulinum neurotoxin.
E. M. Eliseeva   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy